Browsing Tag
dementia with Lewy bodies
4 posts
Why CGTX stock could draw attention after FDA alignment on DLB psychosis
Cognition Therapeutics’ FDA alignment gives zervimesine a clearer DLB psychosis path, sharpening CGTX’s dementia drug development and stock story.
What clinicians and regulators will watch next after neflamapimod’s MRI results
CervoMed Inc. (NASDAQ: CRVO) reveals neflamapimod MRI data. Discover what clinicians and regulators will watch next in DLB trials.
Zervimesine development highlights regulatory complexity in dementia with Lewy bodies
Zervimesine moves closer to Phase 2b as Cognition Therapeutics engages FDA. Read how regulatory complexity is shaping dementia drug development.
Cognition Therapeutics reports promising Phase 2 results for CT1812 in dementia with Lewy bodies
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage pharmaceutical company focused on neurodegenerative disorder treatment, has reported highly encouraging…